PRTA Valuation

Prothena Corporation PLC

Add to Watchlist

Advanced Chart

10.080

-0.19(-1.850%)1D

PRTA Relative Valuation

PRTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRTA is overvalued; if below, it's undervalued.

Historical Valuation

Prothena Corporation PLC (PRTA) is now in the Fair zone, suggesting that its current forward PS ratio of 10.27 is considered Fairly compared with the five-year average of -2.81. The fair price of Prothena Corporation PLC (PRTA) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：10.38

Fair

-23.92

Trailing

Forward

0.00

EV/EBITDA

Prothena Corporation PLC. (PRTA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -5.75. The thresholds are as follows: Strongly Undervalued below -51.85, Undervalued between -51.85 and -28.80, Fairly Valued between 17.30 and -28.80, Overvalued between 17.30 and 40.35, and Strongly Overvalued above 40.35. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-9.01

EV/EBIT

Prothena Corporation PLC. (PRTA) has a current EV/EBIT of -9.01. The 5-year average EV/EBIT is -1.18. The thresholds are as follows: Strongly Undervalued below -37.03, Undervalued between -37.03 and -19.11, Fairly Valued between 16.74 and -19.11, Overvalued between 16.74 and 34.66, and Strongly Overvalued above 34.66. The current Forward EV/EBIT of -9.01 falls within the Historic Trend Line -Fairly Valued range.

10.27

Prothena Corporation PLC. (PRTA) has a current PS of 10.27. The 5-year average PS is 83.05. The thresholds are as follows: Strongly Undervalued below -251.78, Undervalued between -251.78 and -84.36, Fairly Valued between 250.46 and -84.36, Overvalued between 250.46 and 417.87, and Strongly Overvalued above 417.87. The current Forward PS of 10.27 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Prothena Corporation PLC. (PRTA) has a current P/OCF of 0.00. The 5-year average P/OCF is -7.54. The thresholds are as follows: Strongly Undervalued below -120.15, Undervalued between -120.15 and -63.84, Fairly Valued between 48.77 and -63.84, Overvalued between 48.77 and 105.08, and Strongly Overvalued above 105.08. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-4.66

P/FCF

Prothena Corporation PLC. (PRTA) has a current P/FCF of -4.66. The 5-year average P/FCF is 11.67. The thresholds are as follows: Strongly Undervalued below -343.08, Undervalued between -343.08 and -165.70, Fairly Valued between 189.05 and -165.70, Overvalued between 189.05 and 366.42, and Strongly Overvalued above 366.42. The current Forward P/FCF of -4.66 falls within the Historic Trend Line -Fairly Valued range.

Prothena Corporation PLC (PRTA) has a current Price-to-Book (P/B) ratio of 1.70. Compared to its 3-year average P/B ratio of 3.02 , the current P/B ratio is approximately -43.55% higher. Relative to its 5-year average P/B ratio of 3.79, the current P/B ratio is about -55.01% higher. Prothena Corporation PLC (PRTA) has a Forward Free Cash Flow (FCF) yield of approximately -0.34%. Compared to its 3-year average FCF yield of -14.72%, the current FCF yield is approximately -97.69% lower. Relative to its 5-year average FCF yield of -9.51% , the current FCF yield is about -96.42% lower.

1.70

P/B

Median3y

3.02

Median5y

3.79

-0.34

FCF Yield

Median3y

-14.72

Median5y

-9.51

Competitors Valuation Multiple

The average P/S ratio for PRTA's competitors is 18.78, providing a benchmark for relative valuation. Prothena Corporation PLC Corp (PRTA) exhibits a P/S ratio of 10.27, which is -45.32% above the industry average. Given its robust revenue growth of -96.65%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PRTA.O

Prothena Corporation PLC

Bicycle Therapeutics PLC

Ventyx Biosciences Inc

9.00

641.78M

DRUG.O

Bright Minds Biosciences Inc

73.61

406.18M

Performance Decomposition

Market capitalization of PRTA decreased by 36.64% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -6.08K to -445.01K.

The secondary factor is the Revenue Growth, contributed -96.65%to the performance.

Overall, the performance of PRTA in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-96.65%

132.01M → 4.42M

Revenue Growth

7216.07%

-6.08K → -445.01K

Margin Expansion

-7156.06%

0.03 → -1.82

P/E Change

-36.64%